Got it! Let me rewrite the full blog with Yoast readability fixes applied — short sentences, clear subheadings, active voice, and smooth transitions.
We are proud to share a major milestone from our portfolio company, Immusoft Corporation. The California Institute for Regenerative Medicine (CIRM) has awarded Immusoft $15 million in funding. This grant will help advance ISP-001, a groundbreaking therapy for MPS I — a rare and life-threatening childhood disease.
What Is MPS I?
MPS I stands for Mucopolysaccharidosis Type I. It is a rare genetic disorder. Children born with MPS I cannot produce a key enzyme. Without it, harmful substances build up inside their cells.
Over time, this causes severe organ damage. It also leads to cognitive decline and a shortened lifespan. Today, there is no cure. Existing treatments are limited and difficult to sustain long-term.
For these families, the need for a better solution is urgent.
How Does ISP-001 Work?
ISP-001 takes a completely different approach. It reprograms the patient’s own B cells — a type of immune cell. These reprogrammed cells then continuously produce the proteins the body cannot make.
Think of it this way. Instead of giving the patient a drug repeatedly, the therapy turns their own immune system into a sustained treatment source.
This is not a temporary fix. It is designed to work long-term from within the body.
Why This Is a Historic Milestone
ISP-001 is the world’s first clinical-stage engineered B-cell therapy. That alone is significant. But there is more.
For the first time in the cell and gene therapy field, a patient has been successfully re-dosed. The outcomes were positive. This validates both the safety and durability of the therapy.
That is a landmark achievement — not just for Immusoft, but for the entire field.
What the CIRM Grant Means
CIRM is one of the most respected funding bodies in regenerative medicine. Receiving a $15 million award is more than capital. It is a strong signal that the science is credible and the team is executing.
For early-stage biotech, this kind of institutional backing matters. It confirms that ISP-001 is on the right track.
Why We Invested in Immusoft
Early-stage biotech investing requires conviction. You back the science. You back the team.
The Immusoft team, led by Sean Ainsworth, has delivered at every stage. From platform development to first-in-human trials, they have moved with precision and purpose.
This is what meaningful investing looks like. Real science. Real patients. Real progress.
We congratulate Sean and the entire Immusoft team on this milestone. The road ahead is long — but the foundation is strong.
Interested in investing in breakthrough biotech companies like Immusoft? Explore curated deals on Propel(x)
